Publications by authors named "J Koskinas"
Autoimmune hepatitis (AIH) is a rare liver disease, of unknown origin, characterized by considerable heterogeneity. AIH can affect both sexes, of all ages, ethnicities and races. The revised Clinical Practice Guidelines (CPGs) of the Hellenic Association for the Study of the Liver aim to provide updated guidance to clinicians.
View Article and Find Full Text PDFArticle Synopsis
- Patients with liver steatosis and diabetes may benefit from medications like Empagliflozin and Dulaglutide, but studies specifically comparing these drugs are lacking.
- This study involved 78 adults with type 2 diabetes and nonalcoholic fatty liver disease who received either Empagliflozin, Dulaglutide, or other treatments, focusing on liver fat reduction.
- Results showed the Empagliflozin group had greater reductions in liver fat compared to Dulaglutide and the control group, although weight loss occurred in all groups and no improvement in liver fibrosis was observed.*
Hepatitis C virus (HCV) alters gene expression epigenetically to rearrange the cellular microenvironment in a beneficial way for its life cycle. The host epigenetic changes induced by HCV lead to metabolic dysfunction and malignant transformation. Lysine-specific demethylase 1 (LSD1) is an epigenetic controller of critical cellular functions that are essential for HCV propagation.
View Article and Find Full Text PDFAccording to the WHO's recently released worldwide cancer data for 2020, liver cancer ranks sixth in morbidity and third in mortality among all malignancies. Hepatocellular carcinoma (HCC), the most common kind of liver cancer, accounts approximately for 80% of all primary liver malignancies and is one of the leading causes of death globally. The intractable tumor microenvironment plays an important role in the development and progression of HCC and is one of three major unresolved issues in clinical practice (cancer recurrence, fatal metastasis, and the refractory tumor microenvironment).
View Article and Find Full Text PDFSickle cell disease (SCD) is one of the most common monogenic disorders worldwide and liver complications are common in this group of patients. Our study aims to highlight the prevalence of chronic liver complications and the main predisposing factors for advanced liver fibrosis in SCD patients. For this purpose, 219 patients from eight Thalassemia and Sickle Cell Units across Greece enrolled in our study and history of liver related disease complications was recorded, as well as a full laboratory and imaging analysis concerning their liver function.
View Article and Find Full Text PDF